WallStreetZenWallStreetZen

NASDAQ: CLSD
Clearside Biomedical Inc Stock

Overview
ForecastEarningsDividendOwnership
$1.34-0.03 (-2.19%)
Updated Apr 24, 2024
CLSD Price
$1.34
Fair Value Price
N/A
Market Cap
$100.13M
52 Week Low
$0.65
52 Week High
$2.12
P/E
-2.53x
P/B
-6.29x
P/S
8.79x
PEG
N/A
Dividend Yield
N/A
Revenue
$8.23M
Earnings
-$32.49M
Gross Margin
95.7%
Operating Margin
-394.91%
Profit Margin
-394.9%
Debt to Equity
-3.14
Operating Cash Flow
-$18M
Beta
1.13
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A

CLSD Overview

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Zen Score

–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CLSD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CLSD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CLSD is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
CLSD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more CLSD due diligence checks available for Premium users.

Be the first to know about important CLSD news, forecast changes, insider trades & much more!

CLSD News

Valuation

CLSD fair value

Fair Value of CLSD stock based on Discounted Cash Flow (DCF)
Price
$1.34
Fair Value
-$0.00
Undervalued by
28,014.28%
CLSD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CLSD price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.53x
Industry
15.69x
Market
41.27x

CLSD price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-6.29x
Industry
5.86x

CLSD's financial health

Profit margin

Revenue
$6.3M
Net Income
-$4.8M
Profit Margin
-76.2%
CLSD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CLSD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$34.0M
Liabilities
$49.9M
Debt to equity
-3.14
CLSD's short-term assets ($30.12M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CLSD's long-term liabilities ($43.12M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CLSD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CLSD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$495.0k
Investing
-$120.0k
Financing
-$257.0k
CLSD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CLSD vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CLSD$100.13M-2.19%-2.53x-6.29x
BLUE$100.92M-4.94%-1.54x0.45x
ANIX$101.44M+3.58%-9.35x4.12x
ELYM$101.45M-2.40%-2.82x0.94x
CLRB$98.72M-1.61%-0.98x-72.80x
View Top Biotech Stocks

Clearside Biomedical Stock FAQ

What is Clearside Biomedical's quote symbol?

(NASDAQ: CLSD) Clearside Biomedical trades on the NASDAQ under the ticker symbol CLSD. Clearside Biomedical stock quotes can also be displayed as NASDAQ: CLSD.

If you're new to stock investing, here's how to buy Clearside Biomedical stock.

What is the 52 week high and low for Clearside Biomedical (NASDAQ: CLSD)?

(NASDAQ: CLSD) Clearside Biomedical's 52-week high was $2.12, and its 52-week low was $0.65. It is currently -36.79% from its 52-week high and 106.15% from its 52-week low.

How much is Clearside Biomedical stock worth today?

(NASDAQ: CLSD) Clearside Biomedical currently has 74,721,139 outstanding shares. With Clearside Biomedical stock trading at $1.34 per share, the total value of Clearside Biomedical stock (market capitalization) is $100.13M.

Clearside Biomedical stock was originally listed at a price of $7.25 in Jun 2, 2016. If you had invested in Clearside Biomedical stock at $7.25, your return over the last 7 years would have been -81.52%, for an annualized return of -21.43% (not including any dividends or dividend reinvestments).

How much is Clearside Biomedical's stock price per share?

(NASDAQ: CLSD) Clearside Biomedical stock price per share is $1.34 today (as of Apr 24, 2024).

What is Clearside Biomedical's Market Cap?

(NASDAQ: CLSD) Clearside Biomedical's market cap is $100.13M, as of Apr 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Clearside Biomedical's market cap is calculated by multiplying CLSD's current stock price of $1.34 by CLSD's total outstanding shares of 74,721,139.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.